{"pre_text": ["abiomed , inc .", "and subsidiaries notes to consolidated financial statements 2014 ( continued ) note 10 .", "commitments and contingencies the following is a description of the company 2019s significant arrangements in which the company is a guarantor .", "indemnifications 2014in many sales transactions , the company indemnifies customers against possible claims of patent infringement caused by the company 2019s products .", "the indemnifications contained within sales contracts usually do not include limits on the claims .", "the company has never incurred any material costs to defend lawsuits or settle patent infringement claims related to sales transactions .", "the company enters into agreements with other companies in the ordinary course of business , typically with underwriters , contractors , clinical sites and customers that include indemnification provisions .", "under these provisions the company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities .", "these indemnification provisions generally survive termination of the underlying agreement .", "the maximum potential amount of future payments the company could be required to make under these indemnification provisions is unlimited .", "abiomed has never incurred any material costs to defend lawsuits or settle claims related to these indemnification agreements .", "as a result , the estimated fair value of these agreements is immaterial .", "accordingly , the company has no liabilities recorded for these agreements as of march 31 , 2012 .", "clinical study agreements 2014in the company 2019s clinical study agreements , abiomed has agreed to indemnify the participating institutions against losses incurred by them for claims related to any personal injury of subjects taking part in the study to the extent they relate to uses of the company 2019s devices in accordance with the clinical study agreement , the protocol for the device and abiomed 2019s instructions .", "the indemnification provisions contained within the company 2019s clinical study agreements do not generally include limits on the claims .", "the company has never incurred any material costs related to the indemnification provisions contained in its clinical study agreements .", "facilities leases 2014the company rents its danvers , massachusetts facility under an operating lease agreement that expires on february 28 , 2016 .", "monthly rent under the facility lease is as follows : 2022 the base rent for november 2008 through june 2010 was $ 40000 per month ; 2022 the base rent for july 2010 through february 2014 is $ 64350 per month ; and 2022 the base rent for march 2014 through february 2016 will be $ 66000 per month .", "in addition , the company has certain rights to terminate the facility lease early , subject to the payment of a specified termination fee based on the timing of the termination , as further outlined in the lease amendment .", "the company has a lease for its european headquarters in aachen , germany .", "the lease payments are approximately 36000 20ac ( euro ) ( approximately u.s .", "$ 50000 at march 31 , 2012 exchange rates ) per month and the lease term expires in december 2012 .", "in july 2008 , the company entered into a lease agreement providing for the lease of a 33000 square foot manufacturing facility in athlone , ireland .", "the lease agreement was for a term of 25 years , commencing on july 18 , 2008 .", "the company relocated the production equipment from its athlone , ireland manufacturing facility to its aachen and danvers facilities and fully vacated the athlone facility in the first quarter of fiscal 2011 .", "in march 2011 , the company terminated the lease agreement and paid a termination fee of approximately $ 0.8 million as a result of the early termination of the lease .", "total rent expense for the company 2019s operating leases included in the accompanying consolidated statements of operations approximated $ 1.6 million , $ 2.7 million and $ 2.2 million for the fiscal years ended march 31 , 2012 , 2011 , and 2010 , respectively .", "future minimum lease payments under all significant non-cancelable operating leases as of march 31 , 2012 are approximately as follows : fiscal year ending march 31 , operating leases ( in $ 000s ) ."], "post_text": ["."], "table": [["fiscal year ending march 31,", "operating leases ( in $ 000s )"], ["2013", "1473"], ["2014", "964"], ["2015", "863"], ["2016", "758"], ["2017", "32"], ["thereafter", "128"], ["total future minimum lease payments", "$ 4218"]], "table_ori": [["Fiscal Year Ending March 31,", "Operating Leases  (in $000s)"], ["2013", "1,473"], ["2014", "964"], ["2015", "863"], ["2016", "758"], ["2017", "32"], ["Thereafter", "128"], ["Total future minimum lease payments", "$4,218"]]}

Question: how much of total future minimum lease payments are due currently?
Evidence:
table_7: fiscal year ending march 31 , the total future minimum lease payments of operating leases ( in $ 000s ) is $ 4218 ;
table_1: fiscal year ending march 31 , the 2013 of operating leases ( in $ 000s ) is 1473 ;
Program: add(1473, 4218), divide(#0, const_2)
Answer:
str_answer: 35%
exe_answer: 2845.5